The estimated Net Worth of Wayde D. Mc Millan is at least $11.4 Milhão dollars as of 3 July 2023. Mr. Millan owns over 1,388 units of Insulet stock worth over $4,890,957 and over the last 6 years he sold PODD stock worth over $2,081,414. In addition, he makes $4,474,090 as Chief Financial Officer, Executive Vice President, e Treasurer at Insulet.
Wayde has made over 5 trades of the Insulet stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,388 units of PODD stock worth $392,721 on 3 July 2023.
The largest trade he's ever made was selling 1,855 units of Insulet stock on 31 December 2021 worth over $498,958. On average, Wayde trades about 366 units every 27 days since 2019. As of 3 July 2023 he still owns at least 21,477 units of Insulet stock.
You can see the complete history of Mr. Millan stock trades at the bottom of the page.
Wayde D. McMillan serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. McMillan has served as our Executive Vice President, Chief Financial Officer and Treasurer since March 2019. From January 2015 to March 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, Mr. McMillan held a variety of leadership positions at Covidien, including Chief Financial Officer and Vice President of Finance of the Medical Devices Group & U.S., Chief Financial Officer and Vice President of Finance of the Surgical Solutions Business Unit, and Vice President Finance and Controller of the Respiratory and Monitoring Solutions Business Unit. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. Mr. McMillan earned his Bachelor of Science in Business Administration from Merrimack College and a Master of Business Administration from the Bentley University McCallum Graduate School of Business.
As the Chief Financial Officer, Executive Vice President, e Treasurer of Insulet, the total compensation of Wayde McMillan at Insulet is $4,474,090. There are 1 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of $5,883,980.
Wayde McMillan is 50, he's been the Chief Financial Officer, Executive Vice President, e Treasurer of Insulet since 2019. There are 16 older and 5 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
Wayde's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, eSamuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: